Real-world outcomes of atezolizumab–bevacizumab and durvalumab–tremelimumab in unresectable hepatocellular carcinoma: a systematic review with covariate-adjusted meta-regression and exploratory machine learning analysis
Background/purposeAtezolizumab–bevacizumab (AB) and durvalumab–tremelimumab (DT) are standard first-line therapies for unresectable hepatocellular carcinoma (uHCC), but their comparative effectiveness remains uncertain.MethodsWe included 76 observation…